肝胆相照论坛

标题: Pevonedistat是一流的NEDD8活化酶抑制剂,是乙型肝炎病毒的有效 [打印本页]

作者: StephenW    时间: 2019-1-11 17:24     标题: Pevonedistat是一流的NEDD8活化酶抑制剂,是乙型肝炎病毒的有效

Pevonedistat, a first‐in‐class NEDD8‐activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus
Kazuma Sekiba
Motoyuki Otsuka
Motoko Ohno
Mari Yamagami
Takahiro Kishikawa
Takahiro Seimiya
Tatsunori Suzuki
Eri Tanaka
Rei Ishibashi
Kazuyoshi Funato
Kazuhiko Koike
First published: 26 December 2018
https://doi.org/10.1002/hep.30491

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.30491

ePDFPDF
Tools
Share
Abstract

Hepatitis B virus (HBV) infection is a major health concern worldwide. To prevent HBV‐related mortality, elimination of viral proteins is considered the ultimate goal of HBV treatment; however, currently available nucleos(t)ide analogs rarely achieve this goal, as viral transcription from episomal viral covalently closed circular DNA (cccDNA) is not prevented. HBV regulatory protein X was recently found to target the protein structural maintenance of chromosomes 5/6 (Smc5/6) for ubiquitination and degradation by DDB1–CUL4–ROC1 E3 ligase, resulting in enhanced viral transcription from cccDNA. This ubiquitin‐dependent proteasomal pathway requires an additional ubiquitin‐like protein for activation, NEDD8. Here, we show that pevonedistat, a first‐in‐class NEDD8‐activating enzyme inhibitor, works efficiently as a novel anti‐viral agent. Pevonedistat significantly restored Smc5/6 protein levels and suppressed viral transcription and protein production in the HBV minicircle system in in vitro HBV replication models and in human primary hepatocytes infected naturally with HBV. Conclusion These results indicate that pevonedistat is a promising compound to treat chronic HBV infection.

This article is protected by copyright. All rights reserved.

作者: StephenW    时间: 2019-1-11 17:24

Pevonedistat是一流的NEDD8活化酶抑制剂,是乙型肝炎病毒的有效抑制剂
Kazuma Sekiba
Motoyuki Otsuka
Motoko Ohno
Mari Yamagami
Takishiro Kishikawa
Takahiro Seimiya
Tatsunori Suzuki
Eri Tanaka
Rei Ishibashi
Kazuyoshi Funato
小池和彦
首次发表:2018年12月26日
https://doi.org/10.1002/hep.30491

本文已被接受发布并经过完整的同行评审,但尚未通过编辑,排版,分页和校对过程,这可能导致此版本与记录版本之间存在差异。请引用本文为doi:10.1002 / hep.30491

ePDFPDF
工具
分享
抽象

乙型肝炎病毒(HBV)感染是全世界主要的健康问题。为了预防HBV相关的死亡,消除病毒蛋白被认为是HBV治疗的最终目标;然而,目前可用的核苷(t)ide类似物很少实现这一目标,因为不会阻止来自附加型病毒共价闭合环状DNA(cccDNA)的病毒转录。最近发现HBV调节蛋白X靶向染色体5/6(Smc5 / 6)的蛋白质结构维持,用于泛素化和DDB1-CUL4-ROC1 E3连接酶的降解,导致cccDNA的病毒转录增强。这种遍在蛋白依赖性蛋白酶体途径需要额外的泛素样蛋白激活,NEDD8。在这里,我们表明pevonedistat,一流的NEDD8激活酶抑制剂,作为一种新型抗病毒剂有效地工作。 Pevonedistat在体外HBV复制模型和HBV天然感染的人原代肝细胞中显着恢复了Smc5 / 6蛋白水平并抑制了HBV小环系统中的病毒转录和蛋白质产生。结论这些结果表明,pevonedistat是治疗慢性HBV感染的有希望的化合物。

本文受版权保护。版权所有。




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5